Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-29T13:57:06.108Z Has data issue: false hasContentIssue false
  • English
  • Français

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants

Published online by Cambridge University Press:  07 November 2014

Robert M. Berman ,
Maurizio Fava ,
Michael E. Thase ,
Madhukar H. Trivedi ,
René Swanink ,
Robert D. McQuade ,
William H. Carson ,
David Adson ,
Leslie Taylor  and
James Hazel
...Show all authors
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: Effective management of major depressive disorder (MDD) continues to be a challenging task for psychiatrists and primary care physicians. This trial evaluated the efficacy and safety of adjunctive aripiprazole versus antidepressant monotherapy in patients with MDD and independently replicated the positive findings of two similar trials.

Methods: Patients (N=1, 147) with MDD experiencing a major depressive episode and a history of inadequate response to antidepressant monotherapy were enrolled (week 0); 827 received single-blind adjunctive placebo plus open-label antidepressant (escitalopram, fluoxetine, paroxetine controlled release, sertraline, or venlafaxine extended release) for 8 weeks to confirm inadequate response to antidepressants; 349 patients with inadequate response were randomized (1:1) to double-blind, adjunctive placebo (n=172) or adjunctive aripiprazole (n=177; 2–20 mg/day). Primary outcome was the mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total score from baseline (week 8) to endpoint (week 14).

Results: Clinically significant improvements in depressive symptoms as assessed by decreases in the MADRS Total score were greater with adjunctive aripiprazole (−10.1) than placebo (−6.4; P<.001). Remission rates were greater for adjunctive aripiprazole than for adjunctive placebo (week 14, 36.8% vs 18.9%; P<.001). Completion rates with adjunctive aripiprazole and placebo were high (83% vs. 87%) and discontinuations due to adverse events were low (6.2% vs 1.7%).

Conclusion: For some patients with MDD who do not obtain adequate symptom relief with antidepressant monotherapy, adjunctive therapies can significantly improve depressive symptoms. As reported, adjunctive aripiprazole was associated with a two-fold higher remission rate than adjunctive placebo. This, and previous studies, have shown that discontinuations due to adverse events were low and completion rates were high, and has indicated that both antidepressant and aripiprazole in combination were relatively well-tolerated and safe. This is the third consecutive clinical trial, in the absence of a failed trial, to demonstrate that aripiprazole augmentation to antidepressants is an efficacious and well-tolerated treatment for patients with MDD who do not respond adequately to standard antidepressant monotherapy (ClinicalTrials.gov study NCT00105196).

Type
Original Research
Information
CNS Spectrums , Volume 14 , Issue 4 , April 2009 , pp. 197 - 206
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Murray, CJ, Lopez, AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504.CrossRefGoogle ScholarPubMed
2.Kessler, RC, Berglund, P, Demler, O, et al.The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.CrossRefGoogle ScholarPubMed
3.Moussavi, S, Chatterji, S, Verdes, E, Tandon, A, Patel, V, Ustun, B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851–858.CrossRefGoogle ScholarPubMed
4.Regier, DA, Narrow, WE, Rae, DS, Manderscheid, RW, Locke, BZ, Goodwin, FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:85–94.Google Scholar
5.Greenberg, PE, Birnbaum, HG, Leong, SA. Cost of depression: current assessment and future direction. Expert Review of Pharmacoeconomics & Outcomes Research. 2001;1:69–76.CrossRefGoogle Scholar
6.Trivedi, MH, Rush, AJ, Wisniewski, SR, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.Google Scholar
7.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al.Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.Google Scholar
8.Gaynes, BN, Rush, AJ, Trivedi, MH, et al.Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med. 2008;23:551–560.Google Scholar
9.Berman, RM, Marcus, RN, Swanink, R, et al.The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843–853.Google Scholar
10.Marcus, RN, McQuade, RD, Carson, WH, et al.The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:156–165.Google Scholar
11.Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
12.Fava, M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649–659.Google Scholar
13.Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.CrossRefGoogle ScholarPubMed
14.Leon, AC, Shear, MK, Portera, L, Klerman, GL. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol. 1992;27:78–82.CrossRefGoogle ScholarPubMed
15.Guy, W. Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Publication (ADM) 76-338. National Institute of Mental Health; 1976:218–222.Google Scholar
16.Rush, AJ, Gullion, CM, Basco, MR, Jarrett, RB, Trivedi, MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477–486.CrossRefGoogle ScholarPubMed
17.Rush, A, Trivedi, M, Ibrahim, HM. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–583.Google Scholar
18.Endicott, J, Nee, J, Harrison, W, Blumenthal, R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321–326.Google ScholarPubMed
19.Einarson, TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol. 2004;19:305–310.Google Scholar
20.Gorwood, P, Weiller, E, Lemming, O, Katona, C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry. 2007;15:581–593.Google Scholar
21.Mittmann, N, Mitter, S, Borden, EK, Herrmann, N, Naranjo, CA, Shear, NH. Montgomery-Asberg severity gradations. Am J Psychiatry. 1997;154:1320–1321.Google Scholar
22.Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19.CrossRefGoogle ScholarPubMed
23.Guy, W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Department of Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health; 1976:534–537.Google Scholar
24.Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676.Google Scholar
25.Labbate, LA, Lare, SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom. 2001;70:221–225.CrossRefGoogle ScholarPubMed
26.Mojtabai, R. Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom. 2008;77:83–92.Google Scholar
27.Trivedi, MH, Fava, M, Wisniewski, SR, et al.Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–1252.Google Scholar
28.Trivedi, MH, Rush, AJ, Gaynes, BN, et al.Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology. 2007;32:2479–2489.CrossRefGoogle ScholarPubMed
29.Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–260.Google Scholar
30.Fava, M, Evins, AE, Dorer, DJ, Schoenfeld, DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115–127.Google Scholar
31.Corruble, E, Legrand, JM, Zvenigorowski, H, Duret, C, Guelfi, JD. Concordance between self-report and clinician's assessment of depression. J Psychiatr Res. 1999;33:457–465.Google Scholar